Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
38 stopped studies mapped to Esophageal Squamous Cell Carcinoma and descendants · 95% state a reason
Over the 38 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04949256 | Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus… | Phase 3 | terminated | Jul 2, 2021 | Merck Sharp & Dohme LLC | Trial was rendered as cancelled work ongoing in the book of business. | Sponsor / business decision |
| NCT03114319 | Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors | Phase 1 | terminated | Apr 14, 2017 | Novartis Pharmaceuticals | Business reasons and not due to any safety concerns | Safety / toxicity |
| NCT05312372 | S095033 in Combination With Paclitaxel as 2nd- or 3rd-line Treatment in Participants With… | Phase 1 / Phase 2 | withdrawn | Apr 5, 2022 | Institut de Recherches Internationales Servier | Strategic development reasons | Sponsor / business decision |
| NCT05462873 | A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With… | Phase 1 | terminated | Jul 18, 2022 | Novartis Pharmaceuticals | Business decision and not related to safety concerns | Safety / toxicity |
| NCT06560645 | A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic… | Phase 1 | terminated | Aug 19, 2024 | Prelude Therapeutics | Sponsor decision | Sponsor / business decision |
| NCT04272034 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in… | Phase 1 | terminated | Feb 17, 2020 | Incyte Corporation | A business decision was made to discontinue further enrollment. There were no safety concerns that… | Safety / toxicity |
| NCT04000529 | Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected… | Phase 1 | terminated | Jun 27, 2019 | Novartis Pharmaceuticals | Business reasons | Sponsor / business decision |
| NCT06420908 | Adebrelimab Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal… | N/A | withdrawn | May 20, 2024 | Hebei Medical University Fourth Hospital | The primary reason for termination was difficulty in recruitment | Enrollment / accrual |
| NCT03320629 | A Study of Apatinib Plus Radiotherapy and S-1 for Treatment of Refractory or Metastatic… | Phase 2 | terminated | Oct 25, 2017 | Hebei Medical University Fourth Hospital | This study was voluntarily terminated after investigator assessment, with no safety concerns… | Safety / toxicity |
| NCT05834543 | Clinical Trial to Evaluate the Safety and Effectiveness of TQB2618 Injection Combined… | Phase 1 / Phase 2 | terminated | Apr 28, 2023 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | This study was closed due to business reasons. Closure was not prompted by any safety or efficacy… | Safety / toxicity |
| NCT05461794 | Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With… | Phase 2 | terminated | Jul 18, 2022 | BeiGene | Due to modification of company strategy. | Sponsor / business decision |
| NCT04032704 | A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors | Phase 2 | terminated | Jul 25, 2019 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT04804696 | Toripalimab with Paclitaxel and Cisplatin As Neoadjuvant Treatment for Esophageal… | Phase 2 | terminated | Mar 18, 2021 | Peking University | Several clinical trials had showed that anti-PD-1 agents combined with chemotherapy as neoadjuvant… | Other (stated, no rule matched) |
| NCT06702384 | Molecular Analysis of Gastric and OEsophageal Cancers STudy(MAGnET) | — | withdrawn | Nov 25, 2024 | Royal Marsden NHS Foundation Trust | Never opened to recruitment due to lack of funding | Enrollment / accrual |
| NCT06034860 | Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With… | Phase 1 | terminated | Sep 13, 2023 | Molecular Templates, Inc. | Sponsor Termination | Other (stated, no rule matched) |
| NCT04244552 | A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies | Phase 1 | terminated | Jan 28, 2020 | Atreca, Inc. | Sponsor Decision | Sponsor / business decision |
| NCT03251417 | Apatinib and Irinotecan Combination Treatment in Unresectable or Metastatic Esophageal… | Phase 2 | terminated | Aug 16, 2017 | Peking University | Because PD-1 antibodies had been proved to be a standard second-line treatment in esophageal… | Other (stated, no rule matched) |
| NCT04060342 | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With… | Phase 1 | terminated | Aug 19, 2019 | GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. | No clear benefit of GB1275 was observed either as monotherapy or in combination with pembrolizumab. | Other (stated, no rule matched) |
| NCT04625543 | Neoadjuvant Immunotherapy to ESCC | Phase 2 | withdrawn | Nov 12, 2020 | Qilu Hospital of Shandong University | insufficient money | Other (stated, no rule matched) |
| NCT03278626 | Immune Checkpoint Therapy With Nivolumab Esophageal Squamous Cell Carcinoma | Phase 1 / Phase 2 | terminated | Sep 11, 2017 | NYU Langone Health | The study was stopped earlier than anticipated due to slow accrual | Enrollment / accrual |
| NCT03592407 | Epacadostat and Pembrolizumab Before Surgery in Treating Participants With Stage II-III… | Phase 2 | withdrawn | Jul 19, 2018 | City of Hope Medical Center | Safety concerns | Safety / toxicity |
| NCT02272699 | Neoadjuvant Treatment of Nimotuzumab With Chemotherapy or Radiotherapy in Resectable… | Phase 2 / Phase 3 | withdrawn | Oct 23, 2014 | Peking University | Because there are questions about adjuvant radiotherapy in this study, the clinical trial is under… | Other (stated, no rule matched) |
| NCT04084158 | A Study of Toripalimab Combined With Concurrent Chemoradiotherapy for Locally Advanced… | Phase 2 | suspended | Sep 10, 2019 | Zhejiang Cancer Hospital | combination arm delevelped significant poor prognosis | Other (stated, no rule matched) |
| NCT00064259 | A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal… | Phase 1 / Phase 2 | terminated | Jul 9, 2003 | National Cancer Institute (NCI) | Discontinued development of G3139 (oblimersen) | Other (stated, no rule matched) |
| NCT02017600 | A Phase II Trial of Induction Chemotherapy With ND-420, Cisplatin and Fluorouracil… | Phase 2 | terminated | Dec 23, 2013 | Nang Kuang Pharmaceutical Co., Ltd. | not stated | Not stated |
| NCT03206125 | NCI UNC Project ESCC | — | terminated | Jul 2, 2017 | National Cancer Institute (NCI) | determined not to be human subjects research | Other (stated, no rule matched) |
| NCT01498757 | Genome-wide Association Study | — | withdrawn | Dec 23, 2011 | Samsung Medical Center | Registration poor | Other (stated, no rule matched) |
| NCT01248299 | Benefit of Chemotherapy Over Best Supportive Care in Metastatic and Squamous Cell-type…(E-DIS) | Phase 2 | terminated | Nov 25, 2010 | Centre Oscar Lambret | not stated | Not stated |
| NCT03223662 | Metabolomic and BH3 Profiling of Esophageal Cancers: Identification of Novel Assessment… | Phase 2 | terminated | Jul 21, 2017 | National Cancer Institute (NCI) | Principal Investigator left the NIH. | Investigator |
| NCT01627379 | Cisplatin and 5-FU +/- Panitumumab for Patients With Nonresectable,Advanced or Metastatic…(POWER) | Phase 3 | terminated | Jun 25, 2012 | AIO-Studien-gGmbH | Sponsor decision due to recommendation of the IDMC. | Sponsor / business decision |
| NCT03307941 | Assessment of Metabolic & Path Response w/ RCT & ImT Before Surgery in Locally Advanced…(ARTEMIS-Eso) | Phase 1 / Phase 2 | withdrawn | Oct 12, 2017 | Jules Bordet Institute | Suspended collaboration with the company providing the study drug | Sponsor / business decision |
| NCT01740375 | Role of Esophagectomy in Complete Responders to CCRT(ESOPRESSO) | Phase 3 | terminated | Dec 4, 2012 | Asan Medical Center | slow recruitment | Enrollment / accrual |
| NCT02023541 | Proton Beam Therapy to Treat Esophageal Cancer | Phase 1 | terminated | Dec 30, 2013 | Washington University School of Medicine | Lack of insurance coverage for proton beam treatment | Other (stated, no rule matched) |
| NCT02033538 | Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel in Squamous Cell… | Phase 2 | withdrawn | Jan 10, 2014 | Zhejiang University | This clinical trial was closed due to slow recruitment of patients. | Enrollment / accrual |
| NCT02034968 | Nimotuzumab Plus Nab-paclitaxel and Cisplatin in Treating Patients With Advanced… | Phase 2 | withdrawn | Jan 14, 2014 | Zhejiang University | No recruitment | Enrollment / accrual |
| NCT02041819 | Neoadjuvant Chemotherapy of Nimotuzumab Plus Nab-Paclitaxel in Squamous Cell Carcinoma of… | Phase 2 | withdrawn | Jan 22, 2014 | Zhejiang University | No recruitment | Enrollment / accrual |
| NCT02011594 | Phase II Study of Maintenance Treatment of Nimotuzumab for Advanced Esophageal Carcinoma | Phase 2 | withdrawn | Dec 13, 2013 | Zhejiang University | There was no participants enrolled in this clinical trial. | Enrollment / accrual |
| NCT00239200 | Lapatinib (GW572016) for Metastatic or Recurrent Squamous Cell Carcinoma Esophagus | Phase 2 | terminated | Oct 14, 2005 | University of Michigan Rogel Cancer Center | notification from sponsor | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Aug 21, 2026source: clinicaltrials